Additive effect of an immunomodulator and broad-spectrum antibiotic in fecal peritonitis

Area of Science:

• Immunology
• Pharmacology
• Infectious Diseases

Background:

• Peritonitis is a severe abdominal infection often leading to sepsis.
• Muramyl dipeptide (MDP) is an immunomodulatory molecule.
• Broad-spectrum antibiotics like cefoxitin are crucial for treating bacterial infections.

Purpose of the Study:

• To investigate the combined effects of muramyl dipeptide and cefoxitin on survival and systemic bacteremia in a rat peritonitis model.
• To determine the optimal timing for administering these agents for maximum therapeutic benefit.

Main Methods:

• Rats were induced with peritonitis using a human fecal inoculum.
• Muramyl dipeptide and cefoxitin were administered at different time points: 24 hours prior to inoculation, at the time of inoculation, or alone.
• Survival rates, systemic bacteremia, and intra-abdominal abscesses were assessed.

Main Results:

• Combining prophylactic cefoxitin with MDP 24 hours prior to bacterial challenge resulted in 100% survival and significantly reduced early bacteremia.
• Pretreatment with MDP or cefoxitin alone yielded lower survival rates (43% and 56%, respectively).
• Administering MDP with cefoxitin at the time of inoculation did not enhance survival compared to cefoxitin alone.

Conclusions:

• Pretreatment with muramyl dipeptide enhances the efficacy of prophylactic cefoxitin in a rat peritonitis model.
• The timing of administration is critical for achieving a synergistic effect between MDP and cefoxitin.
• This study highlights a potential adjunctive therapeutic strategy for severe bacterial infections like peritonitis.